Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
06 October 2020 | Story Nonsindiso Qwabe | Photo Supplied
Leah Molatseli is the founder of Lenoma Legal, a legal technology company which specialise in commercial and labour matters for small and medium businesses.

Legal technology and innovation specialist and member of the University of the Free State Council, Leah Molatseli, tackled the intersection of law and technology in her new book, titled #LegalTech Startups and Innovation

As technology continues to revolutionise how traditional industries function, legal tech is no longer a foreign concept in the country’s current legal market. The technological boom that has occurred over the past few decades has reshaped many industries. Molatseli said her book is a bridge in the knowledge gap; it is a comprehensive guide for using new technologies in order to provide legal services that are not restricted by physical barriers. 

Molatseli said in her career as a lawyer, she has witnessed first-hand the need for ordinary citizens to gain greater access to justice.  This has led her to adopt new technology that works for the client by cutting costs, improving efficiency, and reaching people more effectively. In 2017, she co-founded Lenoma Legal, a legal tech start-up that provides legal services virtually. 

“While a digital divide still exists, mobile penetration has increased drastically in the past few years, making it much easier to provide legal help from anywhere. My hope is that this book will open up different avenues for law firms, entrepreneurial people who want to innovate within the legal space, and Law students to start thinking differently about how they can shape their careers.”

Technology pivotal to legal industry

Molatseli said she decided at the beginning of 2020 to put the knowledge she gained into a book. When the COVID-19 pandemic hit South Africa, it quickly became apparent that the legal profession had to seek alternative ways to carry out its functions, and the pivotal role that technology has played made the book a timely release. 

“The pandemic has cemented the need for access from anywhere in the world. For me, it’s about access. I believe that access to legal services is a basic human right, and legal tech and innovation plays a huge role in making that happen,” she said. 

Molatseli said #Legaltech Startups and Innovation is a guide that will equip other forward-thinking practitioners to do exactly the same. She said as technology continued to advance, it is becoming easier for anyone within the legal world to create and build solutions.

Book shines light on new avenues in law

“For many years we’ve been made to think that legal careers are linear; get your degree and go work in a law firm, but it’s no longer like that. There are so many avenues open to people within the law industry, and the moment you become aware of this, you can take charge of your career. If we can integrate this type of thinking, the opportunities are endless. This book can drastically change how we do things and how we approach law.”

The book is available for ordering from: https://juta.co.za/catalogue/legaltech-startups-and-innovation_28319/. If you would like to get more information on the book, follow Leah Molatseli on Twitter at @leahmolatseli. 

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept